Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab dose escalation in Japanese Crohn's Disease
NCT01958827Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Sep 2013
- Primary completion
- Mar 2015
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 3 trial of adalimumab in Crohn's disease, sponsored by AbbVie Inc.. Started Sep 2013; status: completed.
02
Drugs
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT01958827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01958827.